|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-6-16
|
|
pubmed:abstractText |
Thoracic malignancies and human breast cancer (HBC) continue to be aggressive solid tumors that are poor responders to the existing conventional standard chemotherapeutic approaches. Malignant pleural mesothelioma (MPM) is an asbestos-related tumor of the thoracic pleura that lacks effective treatment options. Altered ubiquitin proteasome pathway is frequently encountered in many malignancies including HBC and MPM and thus serves as an important target for therapeutic intervention strategies. Although proteasome inhibitor Velcade (Bortezomib) has been under clinical investigation for a number of cancers, limited preclinical studies with this agent have thus far been conducted in HBC and MPM malignancies.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1432-0843
|
|
pubmed:author |
pubmed-author:DouQ PingQP,
pubmed-author:LonardoFulvioF,
pubmed-author:PassHarvey IHI,
pubmed-author:PuliyappadambaVineshkumar TVT,
pubmed-author:RishiArun KAK,
pubmed-author:RuckdeschelJohn CJC,
pubmed-author:SharmaSunitaS,
pubmed-author:TarcaAdiA,
pubmed-author:WaliAnilA,
pubmed-author:WangYingY,
pubmed-author:YangHuanjieH
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
66
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
455-66
|
|
pubmed:dateRevised |
2011-2-7
|
|
pubmed:meshHeading |
pubmed-meshheading:19960346-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19960346-Apoptosis,
pubmed-meshheading:19960346-Blotting, Western,
pubmed-meshheading:19960346-Boronic Acids,
pubmed-meshheading:19960346-Breast Neoplasms,
pubmed-meshheading:19960346-Cell Cycle,
pubmed-meshheading:19960346-Cell Line, Tumor,
pubmed-meshheading:19960346-Cisplatin,
pubmed-meshheading:19960346-Dose-Response Relationship, Drug,
pubmed-meshheading:19960346-Drug Delivery Systems,
pubmed-meshheading:19960346-Drug Synergism,
pubmed-meshheading:19960346-Female,
pubmed-meshheading:19960346-Flow Cytometry,
pubmed-meshheading:19960346-Humans,
pubmed-meshheading:19960346-Mesothelioma,
pubmed-meshheading:19960346-Pilot Projects,
pubmed-meshheading:19960346-Protease Inhibitors,
pubmed-meshheading:19960346-Proteasome Endopeptidase Complex,
pubmed-meshheading:19960346-Pyrazines,
pubmed-meshheading:19960346-Signal Transduction,
pubmed-meshheading:19960346-Time Factors
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.
|
|
pubmed:affiliation |
John D. Dingell VA Medical Center, Karmanos Cancer Institute, Wayne State University, VAMC, 4646 John R., Detroit, MI, 48201, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|
